BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Liang J, Bai Y, Ha FS, Luo Y, Deng HT, Gao YT. Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma. World J Gastrointest Oncol 2023; 15(1): 1-18 [PMID: 36684055 DOI: 10.4251/wjgo.v15.i1.1]
URL: https://www.wjgnet.com/2220-315x/full/v15/i1/1.htm
Number Citing Articles
1
Yaxuan Pang, Jing Zhang, Yanan Mou, Yanan Zhai, Nianjun Liu, Liang Yin. Intra-ablational and peri-ablational radiomics based on post-RFA gadoxetic acid disodium-enhanced MRI for predicting short-term prognosis in hepatocellular carcinomaAbdominal Radiology 2026;  doi: 10.1007/s00261-026-05542-w
2
Changlong Hou, Baizhu Xiong, Lei Zhou, Yipeng Fei, Changgao Shi, Xianhai Zhu, Tao Xie, Yulin Wu. Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinomaBMC Cancer 2024; 24(1) doi: 10.1186/s12885-024-12144-6
3
Ming-Zhi Hao, Hai-Lan Lin, Yu-Bin Hu, Qi-Zhong Chen, Zhang-Xian Chen, Lin-Bin Qiu, Duan-Yu Lin, Hui Zhang, De-Chun Zheng, Zhu-Ting Fang, Jing-Feng Liu. Combination therapy strategy based on selective internal radiation therapy as conversion therapy for inoperable giant hepatocellular carcinoma: A case reportWorld Journal of Gastrointestinal Oncology 2025; 17(3): 100861 doi: 10.4251/wjgo.v17.i3.100861
4
Beichuan Pang, Bangyou Zuo, Liang Huang, Xinyu You, Tao Liu, Jianjie Hao, Chengxiang Yuan, Chong Yang, Wan Yee Lau, Yu Zhang. Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinomaInternational Immunopharmacology 2024; 137: 112492 doi: 10.1016/j.intimp.2024.112492
5
Yutao Chen, Desheng Chen, Zhixing Liang, Haoyuan Yu, Haobin Sun, Yongwei Hu, Peng Jiang, Mingshen Zhang, Linsen Ye, Hua Li. Immune checkpoint inhibitors in hepatocellular carcinoma therapy: resistance mechanisms, liver transplantation challenges and management strategiesCancer Drug Resistance 2025;  doi: 10.20517/cdr.2025.120
6
Junning Liu, Guangnian Zhang, Linfeng Yang, Duan Yan, Jiahui Yu, Song Wei, Jijiang Li, Pengsheng Yi. Salvage liver transplantation versus curative treatment for patients with recurrent hepatocellular carcinoma: A systematic review and meta-analysisEuropean Journal of Surgical Oncology 2024; 50(7): 108427 doi: 10.1016/j.ejso.2024.108427
7
Noura A A Ebrahim, Thoraya A Farghaly, Ahmed Abdo El-Sherif, Ahmed M Fahmy, Moamen O Othman, Neveen S Tahoun, Omnia Mohamed Korany, Aya Arafat, Reham Oreaba, Soliman M A Soliman. Clinicopathological insights and management of liver metastases: Current advances and future perspectivesWorld Journal of Hepatology 2025; 17(10): 110026 doi: 10.4254/wjh.v17.i10.110026
8
Yubo Jiang, Xiaofeng Dong, Yingying Zhang, Feiyan Su, Lei Zhao, Xuetao Shi, Jingtao Zhong. Navigating the complexities: challenges and opportunities in conversion therapy for advanced hepatocellular carcinomaClinical and Experimental Medicine 2025; 25(1) doi: 10.1007/s10238-025-01698-9
9
Mingqiang Liu. Effect of regorafenib combined with immunotherapy and arterial chemoembolization on the survival of patients with advanced hepatocellular carcinoma: a retrospective studyAmerican Journal of Translational Research 2025; 17(3): 1962 doi: 10.62347/BXYO6569
10
Peijie Xia, Aibing Xu, Siyuan Tian, Honghua Huang, Miao Ouyang, Shengnan Huang, Hu Xu. Efficacy and Safety Analysis of Local-Systemic Combined Therapy Versus Systemic Therapy Alone in TACE-Resistant Hepatocellular Carcinoma PatientsHepatitis Monthly 2026; 26(1) doi: 10.5812/hepatmon-168214
Write to the Help Desk